$452.44
0.20% yesterday
Nasdaq, Jun 11, 10:07 pm CET
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Vertex Pharmaceuticals Stock price

$452.44
+13.07 2.97% 1M
-15.85 3.38% 6M
+49.74 12.35% YTD
-29.09 6.04% 1Y
+188.55 71.45% 5Y
+326.09 258.08% 10Y
+439.14 3,301.80% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
+0.92 0.20%
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Key metrics

Market capitalization $116.19b
Enterprise Value $110.10b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.92
P/S ratio (TTM) P/S ratio 10.47
P/B ratio (TTM) P/B ratio 7.05
Revenue growth (TTM) Revenue growth 8.98%
Revenue (TTM) Revenue $11.10b
EBIT (operating result TTM) EBIT $4.21b
Free Cash Flow (TTM) Free Cash Flow $-1.26b
Cash position $6.20b
EPS (TTM) EPS $-3.81
P/E forward 30.02
P/S forward 9.74
EV/Sales forward 9.23
Short interest 2.12%
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Vertex Pharmaceuticals forecast:

18x Buy
53%
14x Hold
41%
2x Sell
6%

Analyst Opinions

34 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
53%
Hold
41%
Sell
6%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
11,100 11,100
9% 9%
100%
- Direct Costs 1,551 1,551
16% 16%
14%
9,549 9,549
8% 8%
86%
- Selling and Administrative Expenses 1,518 1,518
23% 23%
14%
- Research and Development Expense 3,821 3,821
13% 13%
34%
4,410 4,410
2% 2%
40%
- Depreciation and Amortization 202 202
3% 3%
2%
EBIT (Operating Income) EBIT 4,208 4,208
2% 2%
38%
Net Profit -989 -989
125% 125%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Neutral
Seeking Alpha
one day ago
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ET Company Participants David M. Altshuler - Executive VP & Chief Scientific Officer Reshma Kewalramani - CEO, President & Director Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Good after...
Neutral
Business Wire
6 days ago
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities...
Positive
The Motley Fool
10 days ago
A new month has arrived. Investors now have a fresh opportunity to buy great stocks.
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 6,100
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today